An accredited, evidence-driven educational conference for clinicians seeking to understand how emerging psychedelic therapies may affect their clinical practice.
Join multidisciplinary experts in Denver for two days focused on new and emerging therapies, patient selection, safety, clinical decision-making, and appropriate implementation.
Psychedelic medicine is rapidly transitioning from academic research to FDA approval and implementation in the clinic. HCPs increasingly encounter patient inquiries about these medications, and must be equipped to competently respond. All healthcare providers must be prepared to answer important questions regarding which patients may benefit, risks and comorbidities, how to safely administer and monitor the drugs, and the role of the multidisciplinary team in optimal patient care. Sessions will also address ethical, regulatory and legal considerations.
Psychedelics in Clinical Medicine 2027 is designed to address questions through a scientific and clinically-focused educational experience. Two days of sessions will prepare targeted attendees—psychiatrists, primary care clinicians, addiction specialists, neurologists, pain specialists, pharmacists, psychologists, nurses, advanced practice professionals, oncology/palliative-care clinicians, and other clinicians—to master this rapidly evolving area of clinical medicine. The intimate and highly interactive format is designed to engage and to facilitate discussions with experts and other clinicians.
Psychedelic medicine is generating extraordinary interest, but clinicians need more than headlines. They need a rigorous understanding of the evidence, the limitations, the safety considerations, and the practical decisions that accompany patient care. This conference is designed to bring those questions into a multidisciplinary clinical forum and help healthcare professionals approach this rapidly evolving field with scientific discipline, appropriate caution, and patient-centered judgment.
Connect with psychiatrists, addiction specialists, primary care clinicians, neurologists, pain specialists, pharmacists, psychologists, nurses, APPs, palliative-care professionals, investigators, health-system leaders, and drug developers interested in the responsible clinical evolution of psychedelic medicine.
Experience interactive patient scenarios, multidisciplinary case discussions, real-world safety questions, and clinical decision points designed to strengthen competence.
Translate current and emerging evidence into practical considerations for patient selection, medication management, monitoring, referral pathways, informed consent, follow-up, and healthcare system readiness.
This educational activity will be accredited for healthcare professionals (including physicians, nurses, and other clinical professionals) seeking evidence-based education in psychedelic medicine.
This conference is intentionally multidisciplinary. It is designed for healthcare professionals who need a clinically rigorous understanding of psychedelic medicine regardless of whether they currently provide psychedelic-related care.
Psychiatrists; psychiatric NPs/PAs; psychologists; addiction medicine specialists; behavioral-health clinicians.
Primary care physicians; neurologists; pain specialists; anesthesiology/pain clinicians; oncologists; palliative-care clinicians; clinical pharmacists; nurses.
Chief medical officers; medical directors; behavioral-health leaders; pharmacy and therapeutics leaders; quality/safety professionals; clinical program administrators.
Clinical investigators; fellows/residents; academic faculty; health-professions educators; others with a professional interest in evidence-based psychedelic medicine.
By the end of the conference, attendees will be able to:
Loading registration options…
A two-day, multidisciplinary clinical education conference focused on the evidence, safety, patient-selection, pharmacologic, ethical, and implementation questions surrounding psychedelic therapies.
The conference is scheduled for May 1-2, 2027 in Denver, Colorado
The meeting is intended for physicians, including psychiatrists, addiction medicine specialists, primary care clinicians, neurologists, pain specialists, oncology and palliative-care clinicians, as well as psychologists, therapists, pharmacists, nurses, NPs/PAs, and other clinicians interested in this rapidly developing area of medicine.
Psychedelics in Clinical Medicine 2027 will offer up to 10 hours of CME and CE credits for targeted attendees.
Yes. The conference is planned as a hybrid event. Final details regarding virtual access, on-demand availability, and credit eligibility will be announced.
Group registration is encouraged. Final group-registration procedures and contact details will be published when registration opens.
Use the “Get Conference Updates” link on this page to receive agenda, faculty, accreditation, venue, and registration announcements.
Receive conference updates, faculty announcements, agenda releases, accreditation information, early-bird registration alerts, and venue details for Psychedelics in Clinical Medicine 2027.
GET CONFERENCE UPDATES